Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide

Jullien, Maxime; Orvain, Corentin; Berceanu, Ana; Couturier, Marie‐Anne; Guillaume, Thierry; Péterlin, Pierre; Garnier, Alice; Bourgeois, Amandine Le; Klemencie, Marion; Schmidt, Aline; Hunault, Mathilde; Roussel, Xavier; Delépine, Pascal; Guillerm, Gaëlle; Giltat, Aurélien; François, Sylvie; Thépot, Sylvain; Gouill, Steven Le; Bene, M. C.; Chevallier, Patrice

doi:10.1002/cam4.4262

Cited by 4 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the elaboration of this score, several changes in clinical practice and patient management may explain this difference. Moreover, HCT-CI was not applicable to alternative graft source [47,48], and a most recent study showed that cancer comorbidity did not impair 2-year OS [49]. These data suggest that this comorbidity score may be not applicable to all AML patients, especially in those with t-AML patient for whom alloHSCT is the only therapeutic option.…”

Section: Declarationsmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC

Rey,

Daguenet,

Bonjean

et al. 2023

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

We report the results from a multicentre retrospective study of 220 adult patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) for therapy-related acute myeloid leukemia (t-AML). Median age at t-AML diagnosis was 56 years, with a prior history of haematological (45%) or gynaecological neoplasia (37%). Median time from cytotoxic exposure to t-AML diagnosis was 54.7 months. At transplant, around 20% of patients had measurable residual disease and 3% of patients were not in complete remission. The median follow-up was 21.4 months (Q1-Q3, 5.9-52.8). At 12 months, overall survival (OS), event-free survival (EFS), and graft-versus-host-disease (GVHD)-free-relapse-free survival (GRFS) were 60.

show abstract

Section: Declarationsmentioning

confidence: 99%